Jazz Pharma Results

Jazz Pharmaceuticals reported second‑quarter 2026 revenue of $1.21 billion, up 15.5 % year‑over‑year, with net income of $342 million. Adjusted earnings per share were $5.71, 9 % below the Zacks consensus estimate of $6.04, while net income fell 8 % YoY. Operating cash flow for the first half reached $824 million; cash and cash equivalents total $1.24 billion against $3.55 billion of debt. The company’s operating margin for the first half stood at 27 %, a slight improvement over the 26 % margin reported in the previous year, reinforcing its ability to manage costs amid rising R&D spend.